MediciNova, Inc.

MNOV Healthcare Biotechnology

MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.

1.42 0.03 −2.07%
Market cap
$71.4M
P/E
0.0×
Fwd P/E
−5.0×
Dividend yield
—
F-score
n/a
Altman Z
−4.10
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(25.56%) (26.24%) (25.50%) (24.26%)

+8 more TTM periods

ROA
(23.83%) (24.64%) (23.65%) (22.73%)
ROIC
(62.48%) (66.84%) (77.01%) (73.31%)
Return on Tangible Assets
(46.81%) (46.76%) (44.11%) (40.58%)
Average Days of Receivables
0.00 149.95 0.00 0.00
Free Cash Flow per Share
(0.19) (0.19) (0.20) (0.20)
Free Cash Flow
(9.12) (9.51) (9.81) (9.73)
Capital Expenditures
(0.01) (0.01) 0.00 0.00
Other line items
Cash ROIC
(14.55%) (14.25%) (13.55%) (12.71%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.75 0.70 0.44 0.40
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
605.36 567.02 593.61 934.42
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
588.67% 1,102.51% 507.58% 580.43%
Selling, General and Administrative Expense of Revenue
736.61% 1,070.52% 436.95% 454.05%
Share Based Compensation of Revenue
100.26% 159.40% 58.82% 70.44%
Operating CF/Net income
0.85 0.81 0.82 0.81
Depreciation/Fixed assets
1.96 1.29 2.42 1.60
Capex/Depreciation
(0.71) (0.71) (0.13) (0.17)
Revenue per Share
0.02 0.01 0.03 0.03
Operating CF per Share
(0.19) (0.19) (0.20) (0.20)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.01 0.02 0.00 0.00

Fold the line items

Columns are period end dates